Colorectal cancer lymph node staining by activated carbon nanoparticles suspension in vivo or methylene blue in vitro

What Was Tested

The paper reports a study of Methylene blue (non-peptide stack partner), published as a randomized controlled trial.

Who Took Part

The study group was 72 patients.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Sixty-seven of 72 colorectal cancer patients treated at their hospital fulfilled the inclusion criteria of the study which was conducted from December 2010 to February 2012.

Seven patients refused to participate.

How the Study Was Run

In design terms this was a randomized study.

The patients were allocated by chance, so the Methylene blue (non-peptide stack partner) group and the comparison group should start out alike.

Eventually, 60 patients were included, and randomly assigned to three groups (20 in each group): ACNS group (group A), MB group (group B) and non-stained conventional surgical group (group C).

In group C, no ACNS and MB were injected.

All the mesentery lymph nodes were isolated and removed systematically by visually inspecting and palpating the adipose tissue.

What Was Measured

Topics PubMed links to this paper include Carbon, China, Colorectal Neoplasms, Coloring Agents, Injections, Lymph Node Excision and Lymph Nodes.

Author keywords: Activated carbon nanoparticles suspension, Co-lorectal cancer, Methylene blue and Nanotechnology.

What This Means in Plain Language

The paper is a randomized study of Methylene blue (non-peptide stack partner) in 72 patients.

The abstract goes on to report its results in about 16 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2012 (World journal of gastroenterology), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.